AstraZeneca reached a deal with British gene and cell therapy company
Under the agreement,
"We are proud to be a part of this manufacturing consortium working with the
Last week,
AstraZeneca plans to produce at least 400 million doses of the vaccine and has lined up manufacturing capacity for 1 billion doses with first deliveries scheduled for September.
AZD1222 began Phase I/II clinical trials last month to assess safety, immunogenicity and efficacy in more than 1,000 British volunteers last month and is set to enter more advanced trials in June.
Copyright 2020 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source